title: Does protein kinase C play a role in ischemic preconditioning in rat hearts?
abstract: Protein kinase C (PKC) has been implicated in the cardioprotective effects of ischemic preconditioning in rabbits, but whether it plays a role in rats is unknown. We tested this preconditioning PKC theory by assessing whether the inhibition of PKC with calphostin C, a potent and specific inhibitor of PKC, can block the preconditioning effects in this model. Four groups of rats were studied: 1) control + vehicle, 2) control + calphostin C, 3) preconditioning + vehicle, and 4) preconditioning + calphostin C. All rats underwent 90 min of coronary occlusion followed by 4 h of reperfusion; in addition, preconditioned rats underwent three 3-min episodes of ischemia and 5 min of reperfusion before the 90 min of ischemia. Two injections of vehicle or calphostin C (0.1 mg/kg) were administered in intravenous boluses 29 min and 3 min before the 90-min coronary occlusion, i.e., one dose was given 5 min before preconditioning, and another dose was given between preconditioning and the sustained 90 min of ischemia in preconditioned rats. After 4 h of reperfusion, the area at risk (AR) was delineated by dye injection and area of necrosis was assessed by triphenyltetrazolium chloride staining. The electrocardiogram was recorded for the incidence of ventricular tachycardia (VT) and ventricular fibrillation. AR was similar in all four groups. In the nonpreconditioned control rats receiving vehicle, myocardial infarct size expressed as a percentage of the AR averaged 45.7 +/- 1.7%. Pretreatment with calphostin C had no effect on infarct size (48.9 +/- 3.4%) in nonpreconditioned control rats.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Heart Institute, Hospital of the Good Samaritan, Los Angeles, California.
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.forename: R A
authors.initials: RA
authors.lastname: Kloner
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000201:enzymology / Q000503:physiopathology*; D001794:Blood Pressure; D004334:Drug Administration Schedule; D005260:Female; D006339:Heart Rate; D017202:Myocardial Ischemia / Q000201:enzymology / Q000503:physiopathology*; D015425:Myocardial Reperfusion; D009206:Myocardium / Q000201:enzymology* / Q000473:pathology; D009281:Naphthalenes; D009336:Necrosis; D011083:Polycyclic Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D011292:Premedication; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values; D013997:Time Factors
chemical_list: D009281:Naphthalenes; D011083:Polycyclic Compounds; D011493:Protein Kinase C; C058819:calphostin C